Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?

The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase III trial, Boehringer Ingelheim and Eli Lilly announced.

Why did NYU Langone Health abruptly withdraw from a study testing the bacillus Calmette-Guerin vaccine for adolescents with type 1 diabetes? (New York Times)

People with obesity had more than a two-times higher chance of being frail after age 45. “[G]rowing evidence recognizes the subgroup of ‘fat and frail’ older individuals in contrast to viewing frailty only as a wasting disorder,” said researchers in BMJ Open.

The FDA cleared the prescription-only mobile app Tidepool Loop, to be used with compatible devices to automate insulin dosing for managing type 1 diabetes in those ages 6 years and older, the agency announced.

Zoledronic acid (Reclast) given on postoperative day 3 didn’t stunt healing of intertrochanteric fragility fractures when compared with giving the treatment after fracture healing. (Cureus)

From the do-not-do-this department, some people are turning to mixing up raw chemicals to make DIY semaglutide amid Novo Nordisk’s supply shortages of Ozempic and Wegovy. (Jezebel)

Meanwhile, Eli Lilly is trying to mitigate its own diabetes supply shortages by investing $450 million in a North Carolina manufacturing facility. (Drug Delivery Business News)

The U.S. Preventive Services Task Force is now accepting public comment on its draft research plan for chronic kidney disease screening.

While body dissatisfaction can drive eating disorders at any age, this is especially true during perimenopause. (Menopause)